Online inquiry

IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14150MR)

This product GTTS-WQ14150MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14150MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6603MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ10255MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ823MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ6133MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ9557MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ13024MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ15079MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ9072MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW